IMMNOV — Immunovia AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK136.55m
- SEK80.94m
- SEK0.69m
Brief: Immunovia Q1 Operating Loss At SEK 18.4 Mln
Sweden's Immunovia Q1 net sales rise, cash burn falls below guidance
Sweden's Immunovia Q4 operating loss narrows on reduced cash burn
Brief: Immunovia Q4 Oper Loss SEK 16.7 Mln
Brief: Immunovia Board Withdraws Reverse Share Split Proposal, Cancels Meeting
Brief: Immunovia Gets State Regulatory Approval For Pancreasure In California
Brief: Immunovia Board Proposes Reverse Share Split
Brief: Immunovia Receives Final Medicare Payment Rate For Pancreasure Test
Brief: Immunovia Q3 Oper Loss At SEK 25.5 Mln
Brief: Immunovia Announces Outcome Of Rights Issue
Brief: Immunovia To Receive About SEK 100 Mln From Rights Issue
Brief: Inova Schar Cancer Adopts Immunovia’S Pancreasure Test For Its High-Risk Surveillance Program
Brief: Immunovia Says CMS Sets Prelim Price Of $897 For Pancreasure Test
Brief: Immunovia Enters Into Top Guarantee Commitments For Upcoming Rights Issue
Brief: Immunovia Carries Out Rights Issue, Secures Bridge Loans
Brief: Immunovia Q2 Operating Loss SEK 20.1 Mln
Brief: Immunovia Set To Launch PancreaSure In U.S.
Brief: Immunovia Q1 Revenue SEK 139 Thousand
Brief: Immunovia Announces Determined Exercise Price For Warrants Series To 3